Wolf Herman Fridman
Overview
Explore the profile of Wolf Herman Fridman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
10924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattiuz R, Boumelha J, Hamon P, Le Berichel J, Vaidya A, Soong B, et al.
bioRxiv
. 2025 Jan;
PMID: 39763802
Tertiary lymphoid structures (TLS) are organized immune cell aggregates that arise in chronic inflammatory conditions. In cancer, TLS are associated with better prognosis and enhanced response to immunotherapy, making these...
2.
Dunsmore G, Guo W, Li Z, Bejarano D, Pai R, Yang K, et al.
Sci Immunol
. 2024 Jul;
9(97):eadk3981.
PMID: 39058763
Tumor-associated macrophages (TAMs) are a heterogeneous population of cells whose phenotypes and functions are shaped by factors that are incompletely understood. Herein, we asked when and where TAMs arise from...
3.
Revel M, Artero M, Hamidi H, Grunenwald A, Blasco L, Vano Y, et al.
Oncoimmunology
. 2024 Mar;
13(1):2328433.
PMID: 38487624
Despite the progress of anti-cancer treatment, the prognosis of many patients with solid tumors is still dismal. Reliable noninvasive biomarkers are needed to predict patient survival and therapy response. Here,...
4.
Roland C, Nassif Haddad E, Keung E, Wang W, Lazar A, Lin H, et al.
Nat Cancer
. 2024 Feb;
5(4):625-641.
PMID: 38351182
Based on the demonstrated clinical activity of immune-checkpoint blockade (ICB) in advanced dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS), we conducted a randomized, non-comparative phase 2 trial ( NCT03307616...
5.
Soussan S, Pupier G, Cremer I, Joubert P, Sautes-Fridman C, Fridman W, et al.
Front Immunol
. 2024 Feb;
15:1343020.
PMID: 38318190
The intricate relationship between anti-tumor immunity and autoimmunity is a complex yet crucial aspect of cancer biology. Tumor microenvironment often exhibits autoimmune features, a phenomenon that involves natural autoimmunity and...
6.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, et al.
Clin Cancer Res
. 2022 Nov;
29(7):1279-1291.
PMID: 36374555
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with clear-cell renal cell carcinomas (ccRCC). Although analyses of transcriptome, genetic alterations, and the tumor microenvironment (TME) have shed...
7.
Vano Y, Elaidi R, Phan L, Fridman W, Sautes-Fridman C, Oudard S
Lancet Oncol
. 2022 Jun;
23(7):e318.
PMID: 35772460
No abstract available.
8.
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply
Vano Y, Elaidi R, Phan L, Meylan M, Fridman W, Sautes-Fridman C, et al.
Lancet Oncol
. 2022 Jun;
23(7):e317.
PMID: 35772459
No abstract available.
9.
Vano Y, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al.
Lancet Oncol
. 2022 Apr;
23(5):612-624.
PMID: 35390339
Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal...
10.
Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A, et al.
Immunity
. 2022 Mar;
55(3):527-541.e5.
PMID: 35231421
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of...